19^th Euro Congress on Cancer Science and Therapy July 17-19, 2017 Lisbon, Portugal

Alvaro Macieira-Coelho is a Research Director at the French National Institute of Health. He received an MD from the University of Lisbon, Portugal, and a PhD from the University of Uppsala Sweden. He made an internship at the University Hospital in Lisbon and was a research associate at the Wistar Institute in Philadelphia (USA) and at the Department of Cell Biology of the University of Uppsala (Sweden). He became Head of the Department of Cell Pathology at the Cancer Institute in Villejuif (France) and was a visiting Professor at the University of Linkoping (Sweden). He published 150 papers in professional Journals and 9 books on cancer and aging. He received the following awards: Fritz Verzar Prize (University of Vienna, Austria), “Seeds of Science”, Career Prize (Lisbon, Portugal), Dr. Honoris Causa (University of Linkoping, Sweden), Johananof International Visiting Professor (Institute Mario Negri, Milano, Italy).

Cancer Research, Cell Biology, Cancer and Aging, Molecular Biology

Lillie Shockney, is a two-time breast cancer survivor and an expert and leader in the field of breast cancer treatment. Shockney currently serves as an Associate Professor in the Departments of Surgery and Gynecology and Obstetrics at the John Hopkins University School of Medicine, the University Distinguished Service Assistant Professor of Breast Cancer, and the Administrative Director of The Avon Foundation Breast Center at John Hopkins. She is a nationally recognized public speaker on the subject of breast cancer treatment as well as a published author on the subject. She has written over fifty peer reviewed articles in medical journals and eight books. She was selected as one of the Top 100 Women in Maryland for her leadership and community service efforts.

Breast Cancer, Patient Education Programs, Survivor Volunteer

Sherry Bradford attended undergraduate school at SUNY at Buffalo and was awarded a full tuition scholarship to pursue her PhD graduate degree (Biochemistry) from the University of Buffalo/ Roswell Park Cancer Institute Division of SUNY at Buffalo School of Medical and Biomedical Sciences. During her clinical laboratory vocation, she was solicited by the Chief of Surgery at Millard Fillmore Hospital, Buffalo, NY, to direct the Surgical Research laboratory. There she successfully led the research on the use of human micro vascular umbilical cord endothelium for lining stents. It was while Sherry was at Millard Fillmore Hospital, that she was awarded the “1st Place - Award for Excellence in Research” from the American Federation for Clinical Research In 1997, Dr. Bradford was approached by the Department of Pharmacokinetics, at Millard Fillmore Hospital, to lead their newly formed Pharmacokinetics Oncology Department. As the Principal Investigator, she was charged with the responsibility to develop an in vitro chemo sensitivity test on tumor cells using the flow cytometer. In 2008, Dr Bradford and colleagues form AccuTheranostics and the idea on Oncology Personalized Medicine based on the specific patient’s own biochemical and genetic profile to administer Personalized treatment regimens.Currently, Dr. Bradford sits on the EDITORIAL BOARD of the International Journal of Medical and Health Sciences Research; commence on July 20 2014; and on the EDITORIAL BOARD of Insights in Cancer Research, and has authored and co-authored a number of scientific peer-reviewed manuscripts.She is also a member of many professional organizations including (but not limited to): International Metabolic Cancer Group, AACR, ASCO, and GLIFCA.

Personlised Medicine, Pharmacokinetics Oncology

Liane Deligdisch graduated Medical School in Bucharest, Romania, trained in Obstetrics-Gynecology and Pathology in Israel. In the USA since 1986 she was a resident in Pathology at the Boston Free Hospital for Women (Harvard Medical School) visiting Professor at Magee Women's Hospital, Pittsburgh and Fellow in Perinatal Pathology at the Mount Sinai School of Medicine, New York where she is a Professor of Pathology and Obstetrics-Gynecology since 1986 to present. She founded the Division of Gynecologic Pathology and the Course of Gynecologic Pathology at the Medical School. Member of the French National Academy of Medicine, authored 145 articles in peer-reviewed journals and edited 7 textbooks.

Gynecology, Obstetrics-Gynecology, Gynecologic Pathology

M. Helena Vasconcelos is presently Group Leader of the Cancer Drug Resistance Group at i3S/IPATIMUP & Assistant Professor at the Department of Biological Sciences of FFUP (Faculty of Pharmacy, University of Porto).She initiated her teaching career in 1999, while continuing her research career at IPATIMUP. Her work has led to the validation of therapeutic targets and the identification of "hit" small molecules. Helena has been the PI of national research grants and has also served as referee of research projects for national and international funding agencies. She has been a member of numerous scientific and organizing committees of national and international Meetings, Conferences and Workshops. She has published more than 80 peer-reviewed papers and 3 book chapters, having over 1300 citations.

Cancer Biomarkers, Cancer Drug Resistance, Novel Therapeutics

Audrey Claing has completed her PhD at the University of Sherbrooke (Canada) in 1997. She than joined the laboratory of Dr Robert J Lefkowitz, 2012 Nobel Laureate, for her postdoctoral studies at Duke University (USA). She is now professor of Phamacology and Physiology at the Université de Montréal (Canada). She has published more than 60 papers in reputed journals and greatly advanced research in the field of G protein signaling.

Molecular Pharmacology, Intracellular signalling

Yuxun Wang has combined experiences from academia, big pharma, biotech and CRO companies. In his current role as VP of Biology, he is developing drugs for patients with devastating diseases including cancer. Early in his career, Dr. Wang practiced as a clinical doctor specializing in endocrinology and autoimmune diseases, and studied function of oncogenes. Experiences and expertise are documented in continuous publications throughout research career.

Cancer Drug Discovery, Immune-oncology, Cancer R&D, Cancer Immunotherapy, Cancer Genetics